LeuTech gets FDA committee approval
An advisory panel of the FDA last month voted to recommend marketing approval of a Palatin Technologies radiopharmaceutical imaging agent, LeuTech, for diagnosing appendicitis. Officials of the Princeton, NJ, firm said the FDA’s Medical
An advisory panel of the FDA last month voted to recommend marketing approval of a Palatin Technologies radiopharmaceutical imaging agent, LeuTech, for diagnosing appendicitis.
Officials of the Princeton, NJ, firm said the FDAs Medical Imaging Drugs Advisory Committee determined that LeuTech is safe and effective for use in diagnosing appendicitis in patients with uncertain signs and symptoms of the often life-threatening condition.
The panels vote merely suggests approval, but the FDA usually follows the recommendations of its advisory panels, Palatin officials said. The company signed a marketing alliance with St. Louis-based Mallinckrodt last year (SCAN 6/6/99). When LeuTech receives final approval, Mallinckrodt will be in charge of marketing and distributing the radiopharmaceutical. Palatin officials had hoped that LeuTech would be available for sale by the middle of this summer.
The agent binds to white blood cells in vivo, which means that LeuTech can be injected and cells labeled without having to draw blood from the patient (SCAN 5/26/99).
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
